Vifor ended 2021 on a decent note, with a recovering top line and profitability. The Iron franchise was the key driver, whereas Dialysis and Nephrology & Rare disease drug faced some weakness. Overall, the firm has a promising pipeline and, given the fading COVID-19 concerns globally, the momentum of the recovery should be maintained. With respect to the acquisition offer from CSL, management expects to receive all approvals by mid-2022, and closure of the deal is targeted by Q3 22.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Decent end to 2021; set to be acquired by CSL
- Published:
21 Feb 2022 -
Author:
Anas PATEL -
Pages:
3
Vifor ended 2021 on a decent note, with a recovering top line and profitability. The Iron franchise was the key driver, whereas Dialysis and Nephrology & Rare disease drug faced some weakness. Overall, the firm has a promising pipeline and, given the fading COVID-19 concerns globally, the momentum of the recovery should be maintained. With respect to the acquisition offer from CSL, management expects to receive all approvals by mid-2022, and closure of the deal is targeted by Q3 22.